Core Insights - Propanc Biopharma has submitted a request for a foreign filing license from Spain for two provisional patents aimed at treating resistant cancer and fibrosis, marking a significant step in its research and development efforts [1][5] - The first patent focuses on methods to treat cancers that have developed resistance to chemotherapy and radiotherapy, addressing the urgent need for new strategies to prevent recurrence and treatment failure [2] - The second patent pertains to compositions and methods for treating fibrosis, which is characterized by excessive scar tissue accumulation and can affect various organ systems, significantly impacting morbidity and mortality [3] Patent Details - The first provisional patent addresses treatment methods for chemotherapy-resistant cancers, highlighting the ongoing high global mortality rates and the necessity for innovative approaches [2] - The second provisional patent represents a novel addition to Propanc's intellectual property portfolio, utilizing the lead product candidate PRP for chronic diseases beyond cancer, particularly focusing on the epithelial-to-mesenchymal transition (EMT) as a therapeutic target [4] Future Plans - The CEO of Propanc, James Nathanielsz, emphasized that the submission of these patents is a pivotal moment for the company, with plans for a Phase 1b, First-In-Human study in 2026 to determine the therapeutic dose of PRP [5] - The company aims to explore the application of PRP across multiple disease conditions in subsequent Phase 2 proof-of-concept studies, positioning it as a novel therapeutic approach that encourages normal cell behavior without the cytotoxic effects of standard treatments [5] Company Overview - Propanc Biopharma is focused on developing innovative treatments to prevent cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation, with its lead product candidate PRP designed to address the underlying drivers of cancer proliferation [6]

Core Insights - ConnectM Technology Solutions, Inc. has successfully transitioned from the Expert Market to OTCQB, restored its SEC reporting status, and is experiencing revenue growth while developing its Keen Labs platform in the battery and energy storage sectors [1][2][5]. Group 1: Company Progress - The company has executed its plan post-Nasdaq delisting, focusing on current SEC filings, uplisting to OTCQB, revenue growth, and debt reduction [2][4]. - Management has reported double-digit year-over-year revenue growth in each quarter since the Nasdaq delisting, achieving approximately 60% year-to-date revenue growth through Q3 2025 [5][6]. - ConnectM has retired over $10 million in debt and derivative liabilities in 2025, moving from a stockholders' deficit of approximately $50 million to an estimated positive stockholders' equity of around $0.75 million [8]. Group 2: Strategic Developments - The company launched Keen Labs, focusing on AI, industrial IoT, battery systems, and distributed energy platforms, and has made strategic acquisitions to enhance its technology offerings [8][9]. - Acquisitions include Amperics for hybrid battery technology, Geo Impex for an AI-driven data center site, and Air Temp Service Co. and Cambridge Energy Resources Ltd. to expand HVAC services [8]. - A joint venture, StarConnectM LLP, was formed with Star Engineers in India to develop AI-powered connected vehicle platforms [8]. Group 3: Future Outlook - Near- and medium-term priorities include scaling revenue and margins, continuing to reduce liabilities, integrating recent acquisitions, and pursuing targeted M&A in electrification and AI-driven energy infrastructure [9]. - The company is working with ThinkEquity LLC to refine its capital markets strategy and prepare for a potential uplisting to a major U.S. exchange [9].

Core Insights - Yorkville Acquisition Corp. has appointed Steve Gutterman as CEO and Sim Salzman as CFO in connection with the closing of a business combination, which will establish a digital asset treasury company focused on the cryptocurrency token of the Cronos ecosystem (CRO) [1][2] Company Overview - Yorkville Acquisition Corp. is a special purpose acquisition company (SPAC) aiming to merge with established businesses for growth opportunities [8] - Trump Media Group CRO Strategy is focused on strategically investing in digital asset ecosystems and managing CRO [7] Leadership Experience - Steve Gutterman has extensive experience in leading high-growth businesses, overseeing over 40 acquisitions and raising more than $2 billion in capital [2][3] - Sim Salzman has 20 years of finance and accounting experience, with a strong background in high-stakes transactions and digital asset strategy [3] Strategic Vision - The leadership team aims to unlock significant value for shareholders through the aggregation of CRO and effective management of digital assets [2][3] - The business combination is seen as a defining moment for cryptocurrencies and digital asset treasuries, positioning Yorkville Acquisition Corp. uniquely in the market [3] Upcoming Developments - The transition of Gutterman and Salzman into their roles is expected to occur with the closing of the business combination, anticipated in the first quarter of 2026 [4]

Fondsbørsmeddelelse 63/2025Djurslands Bank A/S indberetter hermed på vegne af bankens indberetningspligtige transaktioner med Djurslands Bank A/S-aktier i henhold til Markedsmisbrugsforordningens artikel 19. For yderligere detaljer henvises til vedhæftede skema, hvori transaktioner udført af person med ledelsesansvar og person med nær tilknytning til dem skal indberettes og offentliggøres. Venlig hilsenDjurslands Bank Sigurd Bohlbro SimmelsgaardAdm. bankdirektør Attachments 63.2025 Indberetning Sigurd S ...

Core Insights - SciSparc Ltd. has signed a binding term sheet to acquire patents, trademarks, and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. [1][4] Company Overview - SciSparc operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. Product Details - The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2]. Market Strategy - Following Xylo's successful commercialization in Greater China, SciSparc aims to replicate this model in high-growth regions like North America, Europe, and Latin America by forming exclusive partnerships with regional distributors [3]. Financial Terms of Acquisition - The acquisition will involve SciSparc issuing shares to Xylo, representing 19.99% of the company's issued and outstanding share capital upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5].

Core Insights - Lotus Pharmaceutical has submitted a New Drug Application (NDA) for VIZZ in South Korea, marking the second regulatory submission for the drug outside the U.S. [1] - The NDA submission is backed by positive results from three Phase 3 studies in the U.S., demonstrating VIZZ's effectiveness in improving near vision [2] - Under the licensing agreement, LENZ Therapeutics stands to receive up to $125 million in milestone payments and royalties from future sales of VIZZ [3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, which affects approximately 1.8 billion people globally [10] - Lotus Pharmaceutical, founded in 1966, is an international pharmaceutical company with a strong R&D and manufacturing platform, certified by major regulatory authorities [11] Product Information - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free [6] - The drug is indicated for the treatment of age-related blurry near vision (presbyopia) in adults [7] Market Context - Presbyopia affects nearly all individuals over the age of 45, with significant implications for daily activities and quality of life [5] - The NDA submission in South Korea is part of a broader strategy to expand VIZZ's market presence in Southeast Asia, including countries like Thailand, Vietnam, and Malaysia [3]

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025.Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will participate in ...

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first three patients by the University of Bonn, Germany into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenom ...

Core Viewpoint - RenovoRx, Inc. is actively commercializing its innovative targeted oncology therapies, particularly focusing on the RenovoCath device, which has shown growing clinical demand and market traction [1][2][6] Group 1: Company Updates - CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025, to discuss the company's commercial efforts and market traction [1][4] - Year-to-date revenue for RenovoRx reached approximately $900,000 by the end of September 30, 2025, indicating progress in its commercialization efforts [2][7] - The company has received its first commercial purchase orders for RenovoCath devices and has seen repeat orders from several customers, including high-volume National Cancer Institute-designated centers [7] Group 2: Clinical Research and Development - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine delivered via RenovoCath in patients with locally advanced pancreatic cancer [3][8] - RenovoRx is also conducting a post-marketing registry study to capture real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors [3] - The company supports investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer, which may broaden the application of its TAMP™ therapy platform [3][6] Group 3: Product Information - RenovoCath is an FDA-cleared drug-delivery device designed for targeted therapeutic delivery, aiming to minimize toxicities compared to systemic intravenous therapy [5][6] - The device is indicated for temporary vessel occlusion and the delivery of fluids, including therapeutic agents, to specific sites in the peripheral vascular system [5][9] - RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [10]

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action ...